



NEWS



September 9, 2009

>> 2009 IAS Top Topics

Development of AntiRetroviral Therapy in Africa (DART) Trial

Large-scale, six year study of 3,300 patients, comparing lab-based monitoring vs. clinical monitoring strategy in an ART-treated, African cohort, finding a 3% difference in survival between the two strategies (90% vs. 87% respectively). Considerable debate on these findings has ensued.

HIV-1 Protease inhibitor monotherapy

Two studies, MONET and MONOI-ANRS, investigated the role of darunavir/ritonavir monotherapy in selected patients who were stable on HAART. The results of both studies suggest a potential role of PI monotherapy in selected patients using darunavir/ritonavir. More information: www.vircolab.com

mTB Diagnostics

Despite the alarming prevalence of HIV/m-TB coinfection, the introduction and expansion of anti-HIV therapy may be having a positive impact on mTB prevalence in sub-Saharan Africa.

HIV Resistance Testing

Though little was presented on HIV resistance compared to previous years, research from the group of Dr Richard Harrigan (British Columbia, Canada) focused on comparing Trofile (Monogram Biosciences) testing and Geno2Pheno (Max Planck Institute) genotypic algorithm-based testing in predicting virologic response to maraviroc (Pfizer), the only currently marketed CCR5 antagonist. This study was suggestive of the comparable utility of both approaches.

HIV Pipeline

Most of the IAS coverage on new compounds focused on GSK-364735 (GlaxoSmithKline/Shionogi & Co), a second-generation integrase inhibitor with reported high potency and acceptable tolerability profile, potentially without an overlapping resistance profile to existing marketed or in-development compounds.

Virco Presentations:

Virco BVBA presented one poster and one oral symposium presentation during IAS, these can be found at:

[Conferences & Poster Downloads www.vircolab.com](http://www.vircolab.com)

 [read more](#)

>> Virco Science at HCV 2009

Virco's Dr Theresa Pattery will be presenting a poster at the 6th Annual Symposium on hepatitis C and related Viruses (October 3-7, Nice, France) titled, "Efficiency of NS5B-based HCV subtyping assay is not impacted by HIV co-infection".

 [To view the poster click here](#)

>> Virco at ICAAC / IDSA

Virco will be attending the 49th annual [Interscience Conference on Antimicrobial Agents and Chemotherapy \(ICAAC\)](#) in San Francisco California (September 12-15), and the 47th Annual Meeting of the [Infectious Diseases Society of America \(IDSA\)](#) (October 29 - November 1) in Philadelphia, Pennsylvania. Please come by the virco exhibit and speak to one of our representatives.

 [read more](#)

>> Clinical Update - August 2009

Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals

 **NEW** [on the Virco web site. Click here to read more](#)

>> Virco Quick Spot: "HIV Phenotyping and Viral Mixtures"

Presented by Harold A. Kessler, MD Professor of Medicine and Immunology/Microbiology at Rush University Medical Center in Chicago Illinois (USA).

 **NEW** [on the Virco web site. Click here to read more](#)

[Privacy Policy](#) | [Legal Notice](#) | [Contact us](#) | [Subscribe](#) | [Unsubscribe](#)

VIRCO BVBA
Gen. De Wittelaan L11B3
B-2800 Mechelen
Belgium
Tel: + 32 15 46 1000
Fax: + 32 15 46 1955

Virco Lab Inc.
430 Route 22 East
Bridgewater, NJ 08807
Tel: (908) 541-4499
Fax: (908) 725-6073